Starling Oncology (STLNW) Operating Leases (2022 - 2026)

Starling Oncology (STLNW) has reported Operating Leases for 5 consecutive years, with $24.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 12.52% year-over-year to $24.6 million; the trailing twelve-month figure through Jun 2026 stood at $24.6 million (down 12.52% YoY), and the FY2025 full-year result was $19.1 million, down 17.62% from the prior year.
• Operating Leases fell to $24.6 million in Q2 2026 per STLNW's latest filing, from $26.2 million in the prior quarter.
• Across five years, Operating Leases topped out at $32.6 million in Q2 2023 and bottomed at $18.7 million in Q1 2022.
• Historically, Operating Leases has averaged $26.5 million across 5 years, with a median of $27.2 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Operating Leases surged 70.93% in 2023, then decreased 17.62% in 2025.
• Over 5 years, Operating Leases stood at $22.1 million in 2022, then advanced by 20.06% to $26.5 million in 2023, then fell by 12.32% to $23.2 million in 2024, then fell by 17.62% to $19.1 million in 2025, then increased by 28.63% to $24.6 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $24.6 million, $26.2 million, and $19.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.